title: Malignant melanoma in early-treated Parkinson's disease: the NET-PD trial.
abstract: BACKGROUND
  The risk for malignant melanoma is higher than expected in Parkinson's disease (PD). The National Institutes of Health (NIH) Exploratory Trials in PD (NET-PD) Long-term Study 1 (LS-1) trial is a contemporary phase 3 study of subjects with early, treated PD. The objective of this work was to assess the incidence of malignant melanoma in a PD cohort.
  
  
  METHODS
  Incident melanoma cases were identified from the adverse events log. The expected number of cases was calculated, using the expected incidence rates and the number of person-years.
  
  
  RESULTS
  A total of 618 females and 1119 males were followed for 6452 person-years; 19 new melanoma cases were observed. The expected number was 5.29. The standardized event ratio compared to the general population was 3.6 (95% confidence interval, 2.2-5.6).
  
  
  CONCLUSIONS
  The risk for developing melanoma was higher than expected in the NET-PD LS-1 cohort and was similar to the risk reported in earlier comparable clinical trial cohorts. Dermatologic screening may be useful in Parkinson's disease to identify melanoma at an early stage.
authors: Center for Human Experimental Therapeutics, University of Rochester Medical Center, Rochester, New York, USA.
authors: Radu
authors: R
authors: Constantinescu
authors: Jordan
authors: J
authors: Elm
authors: Peggy
authors: P
authors: Auinger
authors: Saloni
authors: S
authors: Sharma
authors: Erika F
authors: EF
authors: Augustine
authors: Laith
authors: L
authors: Khadim
authors: Karl
authors: K
authors: Kieburtz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008545:Melanoma / Q000139:chemically induced* / Q000453:epidemiology*; D008875:Middle Aged; D009316:National Institutes of Health (U.S.); D018696:Neuroprotective Agents / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000453:epidemiology*; D012642:Selegiline / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000453:epidemiology*; D014481:United States; D055815:Young Adult
chemical_list: D018696:Neuroprotective Agents; D012642:Selegiline
keywords: Parkinson's disease; clinical trial; malignant melanoma; standardized event ratio